MDT

87.11

-0.93%↓

A

115.09

-0.3%↓

VEEV

151.46

-3.57%↓

HQY

78.12

-6.83%↓

TLRY

6.58

-1.94%↓

MDT

87.11

-0.93%↓

A

115.09

-0.3%↓

VEEV

151.46

-3.57%↓

HQY

78.12

-6.83%↓

TLRY

6.58

-1.94%↓

MDT

87.11

-0.93%↓

A

115.09

-0.3%↓

VEEV

151.46

-3.57%↓

HQY

78.12

-6.83%↓

TLRY

6.58

-1.94%↓

MDT

87.11

-0.93%↓

A

115.09

-0.3%↓

VEEV

151.46

-3.57%↓

HQY

78.12

-6.83%↓

TLRY

6.58

-1.94%↓

MDT

87.11

-0.93%↓

A

115.09

-0.3%↓

VEEV

151.46

-3.57%↓

HQY

78.12

-6.83%↓

TLRY

6.58

-1.94%↓

Search

Certara Inc

Fechado

SetorSaúde

5.55 3.16

Visão Geral

Variação de preço das ações

24h

Atual

Mín

5.4

Máximo

5.65

Indicadores-chave

By Trading Economics

Rendimento

-7.4M

-5.9M

Vendas

-968K

104M

P/E

Médio do Setor

100.714

66.418

Margem de lucro

-5.688

Funcionários

1,515

EBITDA

8.6M

32M

Recomendações

By TipRanks

Recomendações

Comprar

Previsão para 12 meses

+63.22% upside

Dividendos

By Dow Jones

Próximos Ganhos

11 de mai. de 2026

Estatísticas de Mercado

By TradingEconomics

Capitalização de Mercado

-164M

870M

Abertura anterior

2.39

Fecho anterior

5.55

Sentimento de Notícias

By Acuity

50%

50%

185 / 348 Ranking em Healthcare

Pontuação Técnica

By Trading Central

Confiança

Very Strong Bearish Evidence

Certara Inc Gráfico

O desempenho passado não é um indicador confiável de resultados futuros.

Notícias Relacionadas

10 de abr. de 2026, 17:04 UTC

Grandes Movimentos do Mercado

FDA Rejects Replimune's Melanoma Drug for a Second Time

11 de abr. de 2026, 00:00 UTC

Ganhos
Aquisições, Fusões, Aquisições de Empresas

Big Yachts, Big Bucks -- Barrons.com

10 de abr. de 2026, 21:55 UTC

Aquisições, Fusões, Aquisições de Empresas

Paramount Warrants Are an Underappreciated Aspect of Warner Bros. Deal -- Barrons.com

10 de abr. de 2026, 21:01 UTC

Ganhos

Cango Inc.: Files Annual Report on Form 20-F With SEC

10 de abr. de 2026, 20:50 UTC

Conversa de Mercado

Energy & Utilities Roundup: Market Talk

10 de abr. de 2026, 20:50 UTC

Conversa de Mercado
Notícias Principais

Basic Materials Roundup: Market Talk

10 de abr. de 2026, 20:50 UTC

Conversa de Mercado

Health Care Roundup: Market Talk

10 de abr. de 2026, 20:31 UTC

Conversa de Mercado

Convenience Store Traffic Slows as Gas Prices Rise -- Market Talk

10 de abr. de 2026, 20:10 UTC

Aquisições, Fusões, Aquisições de Empresas

This Women's Health Company Is Drawing Takeover Interest. The Stock Is Soaring. -- Barrons.com

10 de abr. de 2026, 19:15 UTC

Conversa de Mercado

Global Energy Roundup: Market Talk

10 de abr. de 2026, 19:15 UTC

Conversa de Mercado

Oil Futures Settle Lower With Focus on U.S.-Iran Talks -- Market Talk

10 de abr. de 2026, 19:08 UTC

Conversa de Mercado

Global Forex and Fixed Income Roundup: Market Talk

10 de abr. de 2026, 19:08 UTC

Conversa de Mercado

U.S. Natural Gas Futures End Week Lower -- Market Talk

10 de abr. de 2026, 18:38 UTC

Conversa de Mercado

Canada's Job Market Showing Soft Demand, Structural Decline in Supply -- Market Talk

10 de abr. de 2026, 18:25 UTC

Conversa de Mercado
Notícias Principais

Precious Metals Finish With Weekly Gains -- Market Talk

10 de abr. de 2026, 18:05 UTC

Conversa de Mercado

Rising Commodity Prices Seen Carrying More Weight Than Jobs Data for Bank of Canada Watchers -- Market Talk

10 de abr. de 2026, 17:31 UTC

Conversa de Mercado
Notícias Principais

U.S. Oil Rig Count Unchanged This Week At 411 -- Market Talk

10 de abr. de 2026, 17:26 UTC

Ganhos

Big Banks' Profits Set to Rise Even as 'Wall of Worry' Looms -- Barrons.com

10 de abr. de 2026, 17:10 UTC

Conversa de Mercado

White House Defense of Stablecoin Yields Is Welcome Move, Grayscale Says -- Market Talk

10 de abr. de 2026, 17:00 UTC

Notícias Principais

Construction Business Taking a Hit From Iran Conflict -- WSJ

10 de abr. de 2026, 16:20 UTC

Conversa de Mercado

Health Care Roundup: Market Talk

10 de abr. de 2026, 16:15 UTC

Conversa de Mercado

Global Commodities Roundup: Market Talk

10 de abr. de 2026, 16:12 UTC

Ganhos

Partners Group CEO: Group Well Positioned to Navigate Current Complex Environment

10 de abr. de 2026, 16:11 UTC

Ganhos

Partners Group: Traditional Programs Contributed $3.3B

10 de abr. de 2026, 16:10 UTC

Ganhos

Partners Group: $5B of New Commitments Came From Bespoke Solutions

10 de abr. de 2026, 16:10 UTC

Ganhos

Partners Group: That Is Across All Private Markets Asset Classes and Client Strategies

10 de abr. de 2026, 16:10 UTC

Ganhos

Partners Group 1Q New Client Demand $8.3B

10 de abr. de 2026, 16:09 UTC

Ganhos

Partners Group Continued to See Positive Fundraising Momentum in 1Q

10 de abr. de 2026, 15:54 UTC

Aquisições, Fusões, Aquisições de Empresas

Plenitude Completes Acquisition of Acea Energia

10 de abr. de 2026, 15:38 UTC

Conversa de Mercado

Global Energy Roundup: Market Talk

Comparação entre Pares

Variação de preço

Certara Inc Previsão

Preço-alvo

By TipRanks

63.22% parte superior

Previsão para 12 meses

Média 8.83 USD  63.22%

Máximo 10 USD

Mínimo 7 USD

Com base em 8 analistas de Wall Street que oferecem metas de preço de 12 meses para Certara Inc - Dist nos últimos 3 meses.

Consenso de Avaliação

By TipRanks

Comprar

8 ratings

3

Comprar

5

Manter

0

Vender

Pontuação Técnica

By Trading Central

11.27 / 12.79Suporte e Resistência

Curto Prazo

Very Strong Bearish Evidence

Médio Prazo

Very Strong Bullish Evidence

Longo Prazo

Strong Bullish Evidence

Sentimento

By Acuity

185 / 348 Ranking em Saúde

Sentimento de Notícias

Neutral

Volatilidade

Abaixo da média

Volume de Notícias (RCV)

Média

Informação Financeira

Custos administrativos e de venda

Custos Operacionais

Lucro antes de imposto

Vendas

Custo das vendas

Lucro bruto sobre vendas

Despesa com juros da dívida

EBITDA

Resultado Operacional

$

Sobre Certara Inc

Certara, Inc., together with its subsidiaries, provides software products and technology-enabled services to customers for biosimulation in drug discovery, preclinical and clinical research, regulatory submissions, and market access in the United States and internationally. It offers solutions for model-informed drug development, as well as biosimulation solution used to predict both pharmacokinetics and pharmacodynamics. The company provides Simcyp Simulator, a mechanistic biosimulation platform mechanistic biosimulation investigational new drug and translational stages; Simcyp Biopharmaceutics, used to identify and refine drug formulations; and Simcyp Secondary Intelligence which integrates toxicology with quantitative analysis of networks of molecular and functional biological changes to identify drug toxicity and adverse drug reactions. In addition, it offers Phoenix WinNonlin, a platform for non-compartmental analysis, pharmacokinetic/pharmacodynamic, and toxicokinetic; phoenix hosted, that provides a secured and validated certara amazon web services workspace; Phoenix NLME, a population modeling and simulation software for nonlinear mixed effects models; and pirana modeling workbench. Further, the company provides pinnacle 21, a cloud-based platform for clinical data automation, standardization, and validation; Pinnacle 21 Data Exchange, used to define data standards and specifications; and Metadata Repository, to enable study design using controlled and standardized data. It serves life sciences companies, biopharmaceutical companies, research organizations, academic institutions, and global regulators, as well as animal health, crop science, bio science, medical devices, and public sector industries. Certara Inc. was founded in 2008 and is headquartered in Princeton, New Jersey.
help-icon Live chat